ClinicalTrials.gg
CompletedNCT02604992Updated Jan 20, 2016

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

An interventional study of Treatment A and Treatment B in Healthy, sponsored by INSYS Therapeutics Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-20.

Sponsored by INSYS Therapeutics Inc · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the comparative bioavailability of a test product of dronabinol oral solution administered under fed conditions to the reference listed drug (RLD) administered to participants under fed and fasted conditions.

The secondary objective is to compare the onset of detectable dronabinol concentrations between dronabinol oral solution and the RLD.

02

Conditions studied

  • Healthy

Keywords

  • Comparative Bioavailability
03

In context

Lead sponsor

INSYS Therapeutics Inc is the lead sponsor of 45 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets protocol-specified criteria for qualification
  • Fully comprehends and signs the form, understands all study procedures, and can communicate satisfactorily with the Investigator and study coordinator

Exclusion criteria

Exclusion Criteria:

  • History or current use of over-the-counter medications, dietary supplements, or drugs outside protocol-specified parameters
  • Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

    1. the safety or well-being of the participant or study staff
    2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding)
    3. the analysis of results
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Group 1 (A,B,C)

    With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C

  • Experimental
    Group 2 (B,C,A)

    With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C

  • Experimental
    Group 3 (C,A,B)

    With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C

  • Experimental
    Group 4 (C,B,A)

    With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C

  • Experimental
    Group 5 (A,C,B)

    With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C

  • Experimental
    Group 6 (B,A,C)

    With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C

Interventions

  • DrugTreatment A

    Dronabinol oral solution, under fed conditions

  • Dronabinol oral capsule, under fed conditions

    Also known as: Marinol

  • Dronabinol oral capsule, under fasted conditions

    Also known as: Marinol

06

What researchers measure

Primary outcomes

  1. Area under the curve from time 0 to the last measured concentration

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

  2. Area under the curve extrapolated to infinity

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

  3. Maximum plasma concentration

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

  4. Time to reach maximum plasma concentration

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

  5. Elimination rate constant

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

  6. The time prior to the first measurable (non-zero) concentration

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

  7. Elimination half-life

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

  8. Apparent oral clearance

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

  9. Volume of distribution

    Time frame: 0 hour (predose), 0.08 (5 min), 0.17 (I0 min), 0.25 (15 min), 0.5 (30 min), 0.75 (45 min), 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, and 16 hours postdose.

07

Study locations

1 site
  • Worldwide Clinical Trials Early Phase Services, LLC
    San Antonio, Texas 78217, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2015
First posted
Nov 16, 2015
Start
Nov 2015
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Jan 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02604992
Responsible party
Sponsor
First posted
Nov 16, 2015
Start date
Nov 2015
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Jan 20, 2016

Study contacts

Neha Parikh
study director · INSYS Therapeutics Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion